CASI Pharmaceuticals (CASIF) Cash & Current Investments (2021 - 2025)

CASI Pharmaceuticals has reported Cash & Current Investments for 5 years, with the latest figure at $5.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Current Investments fell 58.18% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $5.6 million (down 58.18% YoY), and the FY2025 full-year result was $5.6 million, down 58.18% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $5.6 million, up from $4.7 million in the prior quarter.
• The five-year high for Cash & Current Investments was $19.9 billion in Q2 2023, with the low at $9533.0 in Q2 2024.
• Historically, Cash & Current Investments has averaged $1.7 billion across 5 years, with a median of $12.8 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Current Investments sank 100.0% — and 2025, when it jumped 70601.77%.
• CASI Pharmaceuticals' Cash & Current Investments stood at $48.6 million in 2021, then advanced by 0.0% to $48.6 million in 2022, then slumped by 40.1% to $29.1 million in 2023, then tumbled by 53.71% to $13.5 million in 2024, then plunged by 58.18% to $5.6 million in 2025.
• The last three Cash & Current Investments figures came in at $5.6 million (Q4 2025), $4.7 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.